ANTIPLATELET ACTIVITY OF ORIGINAL CLOPIDOGREL AND ITS GENERIC: RESULTS OF RANDOMIZED COMPARATIVE CROSS-OVER STUDY
<p><strong>Objective</strong> — to study therapeutic equivalence (efficacy, safety and tolerability) and hemorheological activity of original clopidogrel and its<br />generic in patients of high cardiovascular risk.</p><p><br /><strong>Materials and me...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2014-07-01
|
| Series: | Klinicist |
| Subjects: | |
| Online Access: | http://klinitsist.abvpress.ru/index.php/Klin/article/view/87 |
| Summary: | <p><strong>Objective</strong> — to study therapeutic equivalence (efficacy, safety and tolerability) and hemorheological activity of original clopidogrel and its<br />generic in patients of high cardiovascular risk.</p><p><br /><strong>Materials and methods</strong>. 50 patients with stable angina pectoris were randomized into 2 groups of consecutive 2-week treatment by original<br />(plavix) and generic (plagril) clopidogrel and vice versa. ADP-induced platelet aggregation was measured at baseline and after treatment by<br />each of the drugs. Physical examination and adverse events were evaluated at visits.</p><p><br /><strong>Results</strong>. After the first treatment period a significant decrease of platelet aggregation was determined in both groups. After switching to another<br />drug the decrease continued but not significantly in both groups. There were registered no adverse events associated with antiplatelet therapy.</p><p><br /><strong>Conclusion.</strong> Equal antiplatelet activity established for plavix and plagril demonstrates their therapeutic equivalence.</p> |
|---|---|
| ISSN: | 1818-8338 |